Anika Therapeutics, Inc.
corporate_fare Company Profile
Anika Therapeutics, Inc. (NASDAQ:ANIK) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 13 items for ANIK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-07-29, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 8/10, with 5 rated 8 or above. Recent SEC coverage for ANIK spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Anika Therapeutics Swings to Q2 Profit on 16% Revenue Jump, Margin Expansion
- Record Q2 propels Anika Therapeutics to raise 2026 guidance
- Anika Therapeutics Shareholders Approve 550,000 New Shares for Equity Plans
- Shareholders Approve 550,000 New Shares for Equity Incentive and ESPP Plans
- Anika Therapeutics Reduces Proposed Incentive Plan Dilution After ISS Feedback
Financial Snapshot
Short Interest & Short Volume
5.36 days to coverFINRA reported short interest of 381,376 shares in ANIK as of the September 15, 2026 settlement, a 10.4% increase from the prior period — about 5.4 days to cover at its recent average daily volume. On October 2, 2026, 38.2% of ANIK volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.